Cite
HARVARD Citation
Colman, R. et al. (2021). Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients. Inflammatory bowel diseases. 27 (4), pp. 507-515. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Colman, R. et al. (2021). Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients. Inflammatory bowel diseases. 27 (4), pp. 507-515. [Online].